mci 9038 and glycine
mci 9038 has been researched along with glycine in 15 studies
Research
Studies (15)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC | 1 |
| Verstraete, M | 1 |
| Deinum, J; Elg, M; Gustafsson, D | 1 |
| Deschenes, I; DiMaio, J; Finkle, CD; Leblond, L; St Pierre, A; Winocour, PD | 1 |
| Deinum, J; Nilsson, T; Sjöling-Ericksson, A | 1 |
| Hauptmann, J; Steinmetzer, T; Sturzebecher, J | 1 |
| Fleischer, K; Gulba, DC; Lankes, W | 1 |
| Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
| de Bosch, N; Ebisawa, K; Iwahana, H; Matsudai, M; Ruiz-Sáez, A; Sekine, O; Sugo, T; Umeyama, H | 1 |
| Fenyvesi, T; Harenberg, J; Jörg, I | 1 |
| Fenyvesi, T; Harenberg, J; Joerg, I | 1 |
| Adams, TE; Everse, SJ; Mann, KG | 1 |
| Bauersachs, R; Brehme, S; Caspary, L; Creutzig, A; Harenberg, J; Hoffmann, U; Landgraf, H; Schellong, S | 1 |
| Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE | 1 |
Reviews
6 review(s) available for mci 9038 and glycine
| Article | Year |
|---|---|
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
Advances in the development of thrombin inhibitors.
Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Topics: Angina, Unstable; Antithrombins; Arginine; Glycine; Heparin; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Sulfonamides; Survival Rate; Thrombin | 2002 |
[Prevention and treatment of deep vein thrombosis with ximelagatran].
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Sulfonamides; Thrombin; Venous Thrombosis | 2004 |
Other Studies
9 other study(ies) available for mci 9038 and glycine
| Article | Year |
|---|---|
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin; Male; Molecular Weight; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombolytic Therapy; Thrombophlebitis; Thrombosis | 1996 |
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Topics: Animals; Anticoagulants; Arginine; Arteries; Glycine; Heparin; Hirudins; Humans; Infusions, Intravenous; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombosis; Veins | 1998 |
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
Topics: Antithrombins; Area Under Curve; Arginine; Azetidines; Benzylamines; Binding Sites; Dipeptides; Fluorescence; Glycine; Humans; Kinetics; Molecular Weight; Pipecolic Acids; Piperidines; Spectrometry, Fluorescence; Spectrophotometry; Sulfonamides; Thrombin | 1998 |
Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity.
Topics: Alanine; Amino Acid Substitution; Antithrombin III; Arginine; Binding Sites; Catalytic Domain; Codon; DNA Mutational Analysis; Enzyme Activation; Enzyme Inhibitors; Exons; Factor V; Factor Xa; Glycine; Humans; Models, Molecular; Pipecolic Acids; Polymorphism, Single-Stranded Conformational; Protein Conformation; Prothrombin; Serine; Structure-Activity Relationship; Sulfonamides; Thrombin | 2002 |
Monitoring of anticoagulant effects of direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin | 2002 |
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2002 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2005 |